KPV
Also called Lys-Pro-Val, Lysine-proline-valine.
KPV has no FDA-approved product. This page cites 2 sources, and the strongest evidence comes from animal studies.
- Status
- No FDA-approved product
- Form
- Topical
- Half-life
- Not modeled
- Strongest evidence
- Animal studies
- Cited claims
- 2
- Last updated
- November 6, 2026
What the evidence says
Each claim names the kind of study behind it, what it can't tell you, and where it comes from.
Animal studies
Oral KPV reduced inflammatory findings in chemically induced mouse colitis models, including tissue inflammation and proinflammatory cytokine expression. This was preclinical work with the Lys-Pro-Val tripeptide.
Limits: Mouse colitis is not a controlled treatment study in people with inflammatory bowel disease. The experiment does not establish human clinical remission, chronic safety, or equivalent delivery from commercial capsules, creams, or injections.
Lab studies
In cultured immortalised human bronchial epithelial cells, KPV reduced stimulated NF-kappaB signaling and inflammatory mediator secretion. Investigators studied cellular signaling rather than treating patients with airway disease.
Limits: A study in human-derived cells is not a human treatment trial. Cells received direct laboratory exposure; clinical lung benefit, topical skin efficacy, and effective oral exposure cannot be inferred from these mechanistic findings.
Regulatory status
United States
No FDA-approved product was identified. The October 2026 draft, nonbinding HHS policy addresses KPV acetate for topical and oral preparations under specified conditions. This conditional compounding policy does not establish efficacy or approval. Its scope does not include injectable KPV or the full alpha-MSH peptide.